Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05754957 · ClinicalTrials.gov registry record · Phase 3

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

A Phase 3 study of Acute Coronary Syndrome, sponsored by Janssen Research & Development.

Active
Registry status
Phase 3
Development phase
14,194
Enrollment target
20
Study locations

NCT05754957 is a Phase 3 study of Acute Coronary Syndrome that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 14,194 participants, above the 2,367-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (500% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05754957, a Phase 3 study of Acute Coronary Syndrome, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
14,194 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

Conditions Studied

Acute Coronary Syndrome

Interventions

  • OTHER Placebo
  • DRUG Milvexian

Study Locations (20)

California

  • Bakersfield Memorial Hospital - Bakersfield
  • Mission Cardiovascular Research Institute - Fremont
  • Radin Cardiovascular Medical Group - Newport Beach
  • Valley Clinical Trials, Inc. - Northridge
  • Stanford University School of Medicine - Palo Alto
  • VA Palo Alto Healthcare System - Palo Alto
  • Huntington Hospital - Pasadena
  • The Cardiovascular Center - Redding
  • University Of California San Diego - San Diego
  • San Diego Cardiac Center - San Diego
  • VA San Diego Health Care System - San Diego

Alabama

  • Advanced Cardiovascular, LLC - Alexander City
  • SORRA Research - Birmingham
  • Ascension St. Vincent's Health System - Birmingham
  • IMC-Diagnostic and Medical Clinic - Mobile
  • Cardiology Associates of Mobile Inc - Mobile

Arizona

  • Mercy Gilbert Medical Center - Gilbert
  • Valleywise Health Medical Center - Phoenix
  • HonorHealth Neurology - Scottsdale

Arkansas

  • Arkansas Heart Hospital - Little Rock

Trial Details

FieldValue
Enrollment Target 14,194 participants
Start Date 2023-04-07
Est. Completion 2026-10-19
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05754957

The ClinicalTrials.gov registry entry for NCT05754957 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 14,194 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,367-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (500% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05754957 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT05754957 about?

NCT05754957 is a clinical study titled "A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome". The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

What is the current status of trial NCT05754957?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 14,194 participants. The study started on 2023-04-07. Estimated completion is 2026-10-19.

What conditions does trial NCT05754957 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT05754957?

The interventions under investigation include: Placebo (OTHER), Milvexian (DRUG).

Who is sponsoring clinical trial NCT05754957?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05754957 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Coronary Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.